DelveInsight’s “Catheter-Related Bloodstream Infections Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Catheter-Related Bloodstream Infections market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Catheter-Related Bloodstream Infections drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Catheter-Related Bloodstream Infections treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Catheter-Related Bloodstream Infections: An Overview
Catheter-related bloodstream infection (CRBSI) is defined as the presence of bacteremia originating from an intravenous catheter. It is one of the most frequent, lethal, and costly complications of central venous catheterization and also the most common cause of nosocomial bacteremia.
CRBSI occurs due to organisms like coagulase-negative staphylococcus, Staphylococcus aureus, enteric gram-negative bacilli, enterococci and streptococci, pseudomonas and others. Potential risk factors for CRBSI include underlying disease, method of catheter insertion, site of catheter insertion and duration, and purpose of catheterization.
CRBSI arises from bacterial seeding from biofilms that form on either the inside or outside of indwelling catheters. Biofilms allow the sessile bacteria to survive in a hostile environment and grow languidly. The susceptibility of bacteria in a biofilm to antimicrobial agents is dramatically decreased, by at least 10–100-fold. Adherence of contaminating bacteria to the CVC is a prerequisite for biofilm formation to take place. In the first 2 weeks after catheter placement, the formation of a biofilm on the outside of the CVC and subsequent surface migration of bacteria into the bloodstream is vital for CRBSI to occur.
A catheter-associated bloodstream infection is serious but often can be successfully treated with antibiotics. The catheter might need to be removed if one develops an infection. Different measures are used to reduce the risk of occurrence of CRBSI which include the use of utmost barrier, precautions during catheter insertion, effective cutaneous anti-sepsis, and preventive strategies based on inhibiting microorganisms originating from the skin or catheter hub from adhering to the catheter.
Catheter-Related Bloodstream Infections Market Key Facts
-
The total incident population of CRBSI in the 7MM was found to be around 674,000 in 2020, which is anticipated to increase in the forecasted period.
-
In 2020, Japan had around 141,000 incident cases and 136,000 diagnosed incidence cases.
-
The United States accounted for the highest diagnosed incidence with 318,000 cases in 2020.
-
Among EU4 and the UK, Germany accounted for the highest incident cases of CRBSI with more than 62,000 cases in 2020. Whereas, the lowest number of incident cases was contributed by Spain with about 17,000 cases.
-
As per the analysis, in the US, the incidence of Gram-positive bacteria is more than Gram-negative bacteria and very few are affected by candida species (fungi). Methicillin-susceptible Staphylococcus aureus occupies the maximum patient pool among Gram-positive bacteria, with more than 143,000 cases of this category, in 2020.
-
The estimates show a higher incidence of CRBSI in the US, with about 331,000 cases in 2020.
Catheter-Related Bloodstream Infections Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Catheter-Related Bloodstream Infections pipeline therapies. It also thoroughly assesses the Catheter-Related Bloodstream Infections market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Catheter-Related Bloodstream Infections drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Catheter-Related Bloodstream Infections Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Catheter-Related Bloodstream Infections epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Catheter-Related Bloodstream Infections epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Catheter-Related Bloodstream Infections Epidemiology, Segmented as –
-
Total Incident Population of CRBSI in the 7MM [2019–2032]
-
Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM [2019–2032]
-
Total Diagnosed Incident Population of CRBSI in the 7MM [2019–2032]
Catheter-Related Bloodstream Infections Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Catheter-Related Bloodstream Infections market or expected to be launched during the study period. The analysis covers the Catheter-Related Bloodstream Infections market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Catheter-Related Bloodstream Infections drugs based on their sale and market share.
The report also covers the Catheter-Related Bloodstream Infections pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Catheter-Related Bloodstream Infections companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Catheter-Related Bloodstream Infections Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market
Catheter-Related Bloodstream Infections Therapeutics Analysis
CRBSI various measures have been implemented to reduce the risk of occurrence which includes the use of utmost barrier, precautions during catheter insertion, effective cutaneous anti-sepsis, and preventive strategies based on inhibiting microorganisms originating from the skin or catheter hub from adhering to the catheter.
If the infection is suspected, the first thing suggested by the various guidelines is to remove the catheter. If the patient remains febrile, then antibiotics and antifungal treatments are suggested. Antibiotic therapy is often empirically initiated. This also depends on the patient’s clinical disease, the risk factors for infection, and the likely pathogens associated with the specific intravascular device.
Several gram-positive and gram-negative bacteria form colonies near the site of insertion, and if that happens then, many drugs are prescribed off-label to the patient because as of now, there is no approved therapy for CRBSI in the US, and only antimicrobials are recommended.
Several major pharma and biotech companies are developing therapies for Catheter-related Bloodstream Infections. Currently, Citius Pharmaceuticals is leading the therapeutics market with its Catheter-related Bloodstream Infection drug candidates in the most advanced stage of clinical development.
Catheter-Related Bloodstream Infections Companies Actively Working in the Therapeutics Market Include
-
CorMedix
-
Geistlich Pharma
-
TauroPharm GmbH
-
Fresenius Medical Care
And Many Others
Emerging and Marketed Catheter-Related Bloodstream Infections Therapies Covered in the Report Include:
Mino-Lok: Citius Pharmaceuticals – Citius Pharmaceuticals is conducting a Phase III study to evaluate the efficacy and safety of mino-lok therapy (MLT) in combination with systemic antibiotics in the treatment of catheter-related or central line-associated bloodstream infections. Mino-Lok is an antibiotic lock solution used to treat patients with CLABSIs/CRBSIs. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Catheter-Related Bloodstream Infections Competitive Intelligence Analysis
4. Catheter-Related Bloodstream Infections Market Overview at a Glance
5. Catheter-Related Bloodstream Infections Disease Background and Overview
6. Catheter-Related Bloodstream Infections Patient Journey
7. Catheter-Related Bloodstream Infections Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Catheter-Related Bloodstream Infections Treatment Algorithm, Current Treatment, and Medical Practices
9. Catheter-Related Bloodstream Infections Unmet Needs
10. Key Endpoints of Catheter-Related Bloodstream Infections Treatment
11. Catheter-Related Bloodstream Infections Marketed Therapies
12. Catheter-Related Bloodstream Infections Emerging Drugs and Latest Therapeutic Advances
13. Catheter-Related Bloodstream Infections Seven Major Market Analysis
14. Attribute Analysis
15. Catheter-Related Bloodstream Infections Market Outlook (In US, EU5, and Japan)
16. Catheter-Related Bloodstream Infections Companies Active in the Market
17. Catheter-Related Bloodstream Infections Access and Reimbursement Overview
18. KOL Views on the Catheter-Related Bloodstream Infections Market
19. Catheter-Related Bloodstream Infections Market Drivers
20. Catheter-Related Bloodstream Infections Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Hypercoagulability market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hypercoagulability market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology